Liposomal Bupivacaine for Preventing Atrial Fibrillation

This trial explores whether administering liposomal bupivacaine, a long-lasting pain relief medication, before heart surgery can prevent atrial fibrillation, an irregular heartbeat, after the operation. Participants will receive either this medication or a saline placebo, a harmless solution, before surgery. Researchers will monitor heart rhythms using a wearable ECG device. Individuals scheduled for coronary artery bypass surgery, who might require additional heart procedures, could be suitable candidates. As a Phase 4 trial, this research involves an FDA-approved treatment and aims to understand its benefits for a broader patient population.

The trial does not specify if you need to stop taking your current medications, but you cannot participate if you are using anti-arrhythmic drugs (except beta-blockers).

Research has shown that liposomal bupivacaine, used in a procedure called stellate ganglion block, is generally well-tolerated. Studies have found that this nerve block procedure aids recovery after surgery without causing significant side effects. For instance, research on its use for heart rhythm issues did not identify major safety concerns, suggesting it might safely prevent irregular heartbeats post-surgery. Additionally, the FDA has already approved liposomal bupivacaine for other uses, supporting its safety profile. However, as with any medical treatment, individual experiences can vary.¹²³⁴⁵

Unlike standard treatments for preventing atrial fibrillation, which often include medications like beta-blockers or anticoagulants, the use of liposomal bupivacaine offers a novel approach. Researchers are excited about this treatment because it uses a stellate ganglion blockade, which targets nerve activity directly, potentially reducing the risk of atrial fibrillation in a more targeted manner. The liposomal formulation allows for a slow, sustained release of bupivacaine, which might prolong its effects and offer better management of the condition. This method could offer a new way to prevent atrial fibrillation with potentially fewer side effects compared to traditional systemic medications.

This trial will compare the effectiveness of a stellate ganglion block using liposomal bupivacaine with a sham block using a saline placebo. Research has shown that stellate ganglion blockade with liposomal bupivacaine might help reduce irregular heartbeats, including atrial fibrillation. Some studies suggest it can lower abnormal heart rhythms and possibly decrease the risk of atrial fibrillation. Although one study found it did not specifically reduce atrial fibrillation after surgery, it did show improved recovery post-surgery. Additionally, this treatment has effectively controlled other heart issues, such as ventricular tachycardia, suggesting it might help manage atrial fibrillation.¹²⁵⁶⁷